KMT2C and chronic myelogenous leukemia, BCR-ABL1 positive: MLL3/KMT2C showed a significant upregulated expression in CML patients compared to the control group, which decreased gradually through the accelerated and blast phase, although this differential expression among disease stages was not statistically significant.